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Abstract
Background: This study’s objective was to identify adverse events following common orthopaedic procedures, and
to estimate the incidence rates and risks of these events and their associations with age, sex, and comorbidities.
Methods: This retrospective cohort study manually reviewed and extracted electronic medical data on the
incidence and predictors of adverse events that occurred within 90 days of the 50 most frequent orthopaedic
surgeries at an academic hospital in 2010. We also extracted demographic data, baseline comorbidities, and
duration of follow-up (≤90 days). Patients were scored on the Charlson Comorbidity Index (CCI) and the Functional
Comorbidity Index (FCI). We estimated incidence rates and risks for all events and associations using regression
methods. Prolonged pain 42-days post-surgery was treated as a separate outcome.
Results: We included 1,552 patients; average age was 53.4 years, and 51.7% were female. A total of 1,148 adverse
events were identified in 729 patients. The incidence rate of all adverse events was 10 events per 1,000 person-days at
risk; 47% of all patients experienced at least one adverse event within 90 days. The most frequent events were
prolonged pain (31% of all adverse events) and persistent swelling (7%). We found positive associations between both
comorbidity scores and the incidence rate and 90-day risk of all adverse events, excluding pain, adjusting for age and
sex (neither of which was associated with adverse events); the association was stronger for the FCI than for the CCI. For
total hip arthroplasty (THA) and total knee arthroplasty (TKA), the incidence rate of all adverse events, excluding pain,
was positively associated with both comorbidity scores and age; the 90-day risk was positively associate with the FCI
score and male sex. The prevalence of prolonged pain at 42 days was greater in patients with higher FCI scores; for
THA and TKA only, pain prevalence was greater in those with higher FCI scores and in men.
Conclusions: Adverse events are frequent following common orthopaedic procedures. The incidence is greatest for
patients with more functional comorbidities. For THA and TKA procedures, being male and being older are also
associated with a greater incidence of adverse events.
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Background
A large number of adverse events (AE) are encountered
during hospitalization, in particular during and after
surgical procedures [1–5]. The operating room is a com-
plex environment with a number of factors that increase
the risk of AEs [6–12]. In particular, it contains a high
concentration of information, can be very fast paced, has
many patient transfers, and many person-machine inter-
actions [6, 7]. A recent systematic review of the inci-
dence and nature of in-hospital adverse events found
that 58% of all events were related to surgery with
general surgery and orthopaedic surgery being the
largest contributors [10]. In addition, some research
findings suggest that a large proportion of surgical AEs
are preventable (e.g., [9, 10]). Consequently, several
surgical safety mechanisms, including general surgery
checklists, have been developed and tested across several
surgical disciplines [13–16].
For example, the Surgical Safety Checklist (SSC) [13–
16] and the SURgical Patient Safety System (SURPASS)
checklist were developed [15, 16] and both appear to
decrease the risk of complications. These results are
promising but, these checklists do not specifically ad-
dress unique characteristics of individual surgical
specialties. Several researchers have suggested that surgi-
cal safety checklists should be tailored to specific surgi-
cal disciplines, institutions, geographic regions and
countries [e.g, 13,15]. For example, some healthcare in-
stitutions have policies to reduce surgical risk specifically
for patients undergoing orthopaedic surgery [17–25].
To determine where surgical safety initiatives need to
be modified or focused for relevance to orthopaedic sur-
gery, the incidence and predictors of adverse events
must be identified. At this time, however, there is rela-
tively little empirical research on the array of adverse
events across the varied types of orthopaedic interven-
tions. Most research focuses on the risk of adverse
events following total knee and total hip replacement.
For example, Soohoo et al. [26] found that, following
total knee replacement, the 90-day risk was 0.53% for
mortality, 0.71% for serious infection, and 0.41% for
pulmonary embolism [26]. They also reported that the
overall 90-day risk of a complication (i.e., death, serious
infection, pulmonary embolism etc) was positively
associated with age, the Charlson Comorbidity Index,
hospital volume, having private insurance, being male,
and being white. In another study, Pulido et al. [27]
reported 12-month infection risks following hip and knee
arthroplasty of 0.3 and 1.1%, respectively. Stefansdottir et
al. [28] suggested that such infections are closely related
to inadequate timing of prophylactic antibiotics. In
another study of adverse-event frequency for different
orthopaedic procedures, Schilling et al. [29] found a
30-day mortality risk of 0.005% for all procedures. They
found that hip fracture repair accounted for the greatest
share of adverse events (19%), followed by total knee
arthroplasty (18%), total hip arthroplasty (11%), and revi-
sion total hip arthroplasty (5%).
More recently, Browne et al. [30] found that across
over 200,000 patients who underwent total joint arthro-
plasty, the following risks of in-hospital postoperative
complications were found: anemia 16%, cardiac 0.45%,
peripheral vascular 0.1%, respiratory 0.5%, gastrointes-
tinal 0.3%, genitourinary 0.35%, central nervous system
0.1%, hematoma/seroma 0.8%, wound dihescense 0.04%,
infection 0.15%, deep vein thrombosis 0.2%, pulmonary
embolism 0.1% and mortality <0.1%. They also found
that Medicaid patients had a higher risk for some of
these complications.
While these studies are informative, we could not find
any research that comprehensively explored the risk of
adverse events across a wide array of orthopaedic proce-
dures. They do not provide a detailed description of all
types of adverse events in these patients, such that we
can reliably and comprehensively inform safety initiative
development. The objectives of this research were to
extract data on a broad range of adverse events following
orthopaedic surgeries in a hospital population, to esti-
mate and compare the incidence rates and risks of those
adverse events, and to assess associations of adverse
events with selected patient factors and type of surgery.
This information will help inform specific safety system




We conducted a retrospective cohort study by manually
reviewing and extracting from electronic medical
records (EMR) data on the incidence and predictors of
adverse events that occurred within 90 days for the 50
most frequent orthopaedic surgeries performed at the
University of Michigan Health System in 2010. In this
project, an adverse event was any negative patient
outcome that occurred within 90 days of the patient
having surgery and that was described by the investiga-
tors a priori or during data collection as possible
consequences of surgery or hospitalization.
Data source
All EMRs were accessed through CareWeb, a web-based
clinical patient record system developed for use by
clinicians and clinical support staff [31]. We reviewed
and extracted data from the orthopaedic clinical notes,
notification notes, phone notes, imaging documents and
reports.
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Inclusion and exclusion criteria
We included patients who had an orthopaedic surgical
procedure in 2010 for one of the 50 most common
Current Procedural Terminology (CPT) codes (See
Appendix 1). Patients were excluded if their surgery was
a repeat procedure. Patients of any age and with any
comorbidites were included.
Data extraction
One individual (PK) extracted all data into preformatted
excel spreadsheets for all included patients. A random
sample of approximately ten percent of the first 100 pa-
tients was separately and independently reviewed by a
second individual (JG) and a third individual, an ortho-
paedic surgeon, if needed. These individuals then met to
discuss any discrepancies in the extraction through
discussion and further review of the source EMRs.
First, we extracted demographic information from
each patient’s EMR including age, sex, primary diagnoses
related to the surgery (ICD-9 codes), specific type of
surgery (CPT code), comorbidities (ICD-9 codes), and
surgeon identification number. Patient names and
surgeon names were coded by the data extractor and
sent to the investigators to keep them blinded. The
codes were kept in a secure location by the data
extractor and only referred to by that person when
additional data were required.
Adverse events were defined broadly as any of the fol-
lowing: an unintended injury, complication, prolonged
hospital stay (greater than 30 days), disability observed
at the time of discharge, or death. Unintended injuries
or complications included repeat/revision surgery (i.e.,
due to wrong site surgery, long-term bleeding, non-
healing of wound), surgical site infection, deep vein
thrombosis, and the prolonged pain (i.e., 42 days or
more of narcotic medication). Appendix 2 lists the ad-
verse events and their definitions used during the data
extraction process. We also considered events not
predetermined and that were unanticipated but still de-
termined to be possible adverse events by the data ex-
tractors (See Appendix 3 for other adverse events). The
number of days after the orthopaedic surgical procedure
corresponding to each adverse event was also extracted.
Patients were scored on two comorbidity indexes: the
Charlson Comorbidity Index (CCI) [32], which was
based on the prediction of mortality; and the Functional
Comorbidity Index (FCI) [33], which was based on the
prediction of functional status. The CCI contains patient
data on 19 chronic conditions: acquired immune defi-
ciency syndrome, myocardial infarction, congestive heart
failure, peripheral vascular disease, dementia, chronic
pulmonary disease, connective tissue disease, peptic
ulcer disease, leukemia, lymphoma, tumor without me-
tastasis, metastatic solid tumor, moderate or severe renal
disease, cerebrovascular disease, liver disease, and dia-
betes. Each condition is assigned a weight (an integer
from 1 to 6) based on the adjusted association between
that condition and the mortality rate in one year
(reported by Charlson et al. [32]), and the index score is
the sum of the weights for all conditions reported (see
Table 3 in Charlson et al. [32]). There is evidence that
the CCI predicts outcomes following orthopaedic
procedures (e.g., SooHoo et al. [26]).
The FCI was developed by Groll et al. [33] for use in
general populations. They derived the FCI from self-
reported diagnoses of 18 chronic conditions; the selected
conditions predict the physical function subscale (10
items) of the medical outcomes study short form-36
(MOS SF-36). The FCI includes arthritis (osteoarthritis
and rheumatoid), osteoporosis, asthma, angina, neuro-
logical disease, depression, anxiety or panic disorders,
visual impairment, hearing impairment, degenerative
disc disease, obesity (body-mass index > 30), chronic ob-
structive pulmonary disease, congestive heart failure,
heart attack, stroke or transient ischemic attack, periph-
eral vascular disease, diabetes (type I and II), and upper
gastrointestinal disease (see Table 5 in Groll et al. [33]).
We used one of the recommended methods for scoring
the FCI—a simple count of the number of conditions re-
ported by each subject [33]. The FCI includes an import-
ant functional assessment that goes beyond the CCI and
was developed in patients with musculoskeletal condi-
tions and therefore is appropriate in our population.
Statistical analysis
First, we described the demographic, surgical, and co-
morbidity characteristics of patients in the study popula-
tion. For each type of adverse event (except prolonged
pain), we estimated the incidence of that outcome in
three ways: the rate of adverse events within the 90-day
follow-up period (number of outcome events, divided by
total person-time a risk), the 90-day risk (probability of
experiencing at least one outcome event during follow-
up); and the mean number of adverse events per proced-
ure. We also calculated the mean number of days from
surgery to the first occurrence of each type of event, and
we examined the distribution of the number of adverse
events per patient (including and excluding prolonged
pain). For prolonged pain, we estimated the prevalence
at 42 days. Patients lost to follow-up were censored at
their last visit.
We used two methods to model the effects of selected
variables on the risk or incidence rate of adverse events
occurring within 90 days of surgery and the prevalence
ratio of prolonged pain at 42 days. In all models, sur-
geons were treated as random effects using generalized
estimating equations. First, modified Poisson regression
was used to estimate the crude and adjusted risk ratios
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(RR) for the estimated effects of age, sex, and the CCI or
FCI on adverse events within 90 days of surgery; or the
prevalence ratio for prolonged pain at 42 days post-
surgery. This method was also used to estimate the
effects of early adverse events and specific comorbidities
on prolonged pain. Second, negative binomial regression
was used to estimate the crude and adjusted incidence
rate ratios (IRRs) for the effects of age, gender, and the
CCI or FCI (and individual comorbidities) on all adverse
events occurring in patients during the 90-day follow-up
period (i.e., counting all adverse events that occurred in
each patient). We analyzed data in all models separately
for events related to pain and for those undergoing TKA
and THA. We adjusted for follow-up time in all models.
Results
A total of 6,821 patients were seen in the Department of
Orthopaedic Surgery in 2010, of which 1,552 were eli-
gible for this study (see Fig. 1). The average age of all in-
cluded patients was 53.4 years (range, 2–102); 51.7%
were female. A total of 1,148 adverse events were identi-
fied in 729 patients. The mean length of hospital stay
was 3.3 days (range 0–62). The proportion of all 1,552
patients that were not followed for at least 90 days after
surgery was 34.9% (n = 541); of those not followed for at
least 90 days, the mean duration of follow-up was
42.4 days. The rate of adverse events (number of events
per total follow-up time) was 0.01 events per day, or 10
events per 1000 days.
Figure 2 shows the 90-day risk of each type of adverse
event. The number, proportion and estimated 90-day
risk of each type of adverse event as well as the mean
number of days post-op for those events among all
patients is shown in Table 1. A total of 47% of all pa-
tients experienced at least one adverse event. The most
frequent event was prolonged pain, representing 31% of
all adverse events in the study; the 42-day prevalence
was 23%. Sepsis, long-term bleeding, and wrong-site sur-
gery had the lowest risks. There was a large number of
rare adverse events (31% of the total) that we grouped
together as “other” (see Appendix 2 for a complete list
of “other” AEs). Aside from acute loss of blood, most
adverse events tended to occur after hospital discharge.
For procedures done at least 15 times in 2010, Table 2
describes the adverse events. Total hip and knee arthro-
plasty (THA, TKA) were the dominant procedures in
this sample. A total of 53% of all adverse events in the
study were in those patients who underwent THA, TKA,
or arthrodesis in the lumbar spine. The mean number of
AEs per procedure varied appreciably among proce-
dures; it was highest (>1 AE/procedure) for application
of external fixation system (1.48), lumbar arthrodesis
(1.41), open treatment of a femur fracture (1.20), and
debridement (1.18).
The adverse events for the top two procedures,
THA and TKA are listed in Table 3. For THA other
and prolonged pain were by far the most common
adverse events (41.9 and 33% of the total events),
followed by draining of wounds (7.3%). Those under-
going THA did not have any of the following events:
hospital stay longer than 30 days, wrong site surgery,
long term bleeding, or sepsis. For TKA patients, the
most frequent adverse events were prolonged pain
(32.1%) followed by other events (31.7%) and then
persistent swelling (12.8%), with no patients having a
hospital stay longer than 30 days, wrong site surgery,
long term bleeding, or sepsis.
Table 4 shows the number and percentage of patients
by the number of adverse events per patient, including
and excluding prolonged pain. The percentage of all
study patients who experienced more than one adverse
event during the 90-day follow-up period was 16% when
including prolonged pain and 11% when excluding
prolonged pain.
Fig. 1 Patient inclusion flow chart
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Crude and adjusted incidence rate ratios (IRR) from
the negative binomial regression analyses for the rate
of adverse events (excluding prolonged pain) are
shown in Table 5, separately for all study procedures
(Panel A; N = 1192) and for THA and TKA only
(Panel B; N = 413). More comorbidity, as measured by
both the CCI and FCI scores, was positively
associated with the rate of adverse events in the
adjusted analyses involving all procedures, but the
association was stronger for FCI than for the CCI
(adjusted IRR for FCI = 1.34; 95% CI: 1.23 to1.46;
adjusted IRR for CCI = 1.20; 95% CI: 1.11 to 1.31).
Both age and sex were unassociated with the rate of
adverse events. When restricting the analysis to only
TKA and THA procedures, age was positively but
weakly associated with the AE rate in both model 1,
adjusting for sex and CCI (adjusted IRR per 10 years
= 1.15; 95% CI: 1.00 to 1.32) and model 2, adjusting
for sex and FCI (adjusted IRR per 10 years = 1.12;
95% CI: 0.99 to 1.29).
Fig. 2 Ninety-day risk of adverse events across all included patients. *Other adverse events were identified by data extractors during chart review
that were not predefined by the investigator. Examples of other adverse events include: urinary tract infection, urinary reten-tion, foot drop, fever,
hematoma, pneumonia, bronchitis, myocardial infarction, allergic reaction to medication, hemarthrosis, venous thrombosis, significant blood loss
with staple removal, heterotopic ossification
Table 1 Adverse events across all patients






Prolonged paina 360 (31.36) 23.19 —
Persistent swelling 86 (7.40) 5.54 50.12
Draining of wounds 56 (4.87) 3.73 24.78
Non-healing of wound 56 (4.87) 3.61 30.38
Revision within 90 days of procedure 50 (4.36) 3.22 40.96
Acute blood loss anemia 50 (4.36) 3.22 1.92
Surgical site infection 44 (3.83) 2.84 27.09
Neuralgia 32 (2.78) 2.06 56.22
Death 25 (2.18) 1.61 30.44
DVT 21 (1.83) 1.35 21.95
Hospital stay longer than 30 days 10 (0.87) 0.64 41.70
Sepsis 4 (0.35) 0.26 24.00
Long term bleeding 2 (0.17) 0.13 13.00
Wrong site surgery 0 0 0
Otherb 362 (31.53) 23.32 17.47
aProlonged pain was defined as pain requiring narcotics for greater than 42 days or clearly stated in the patient’s chart as prolonged pain
bExamples of other adverse events: urinary tract infection, urinary retention, foot drop, fever, hematoma, pneumonia, bronchitis, myocardial infarction, allergic
reaction to medication, hemarthrosis, venous thrombosis, significant blood loss with staple removal, heterotopic ossification
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Table 6 shows the crude and adjusted associations of
age, sex, and CCI or FCI with the 90-day risk of any ad-
verse event (excluding prolonged pain), using modified
Poisson regression, for all study procedures (Panel A)
and for THA and TKA procedures only (Panel B). In the
adjusted analyses for all procedures, increasing FCI and
CCI scores were associated with a small increased risk
of any AE (adjusted RR for 1 point on the CCI scale =
1.10; 95% CI: 1.02 to 1.18; and adjusted RR for 1 point
on the FCI scale = 1.19, 95% CI: 1.13 to 1.25). Age and
sex were minimally associated with the risk of AEs. In
the adjusted analysis including only those patients
undergoing THA or TKA, men were more likely than
women to experience an AE within 90 days (RR
adjusting for age and CCI = 1.22; 95% CI: 0.98 to 1.51;
RR adjusting for age and FCI = 1.23; 95% CI: 1.01 to
1.51). In these restricted analyses, the comorbidity scores
were not as strongly associated with AEs as in the ana-
lyses of all procedures (adjusted RR for 1 point on the
CCI scale = 1.07; 95% CI: 0.99 to 1.15; and adjusted RR
for 1 point on the FCI scale = 1.13; 95% CI: 1.06 to 1.21).
Table 7 shows the crude and adjusted prevalence ratios
for the associations of age, sex, and CCI or FCI with the
42-day prevalence of prolonged pain, using modified
Poisson regression, for all procedures and for THA and
TKA procedures only. In the analysis of all procedures,
the FCI score was positively associated with the preva-
lence of prolonged pain at 42 days (adjusted prevalence
Table 2 Frequency of procedures and adverse events by type of procedurea
Procedure Type Number of
Procedures






Mean Number of Events
per Procedure
Total hip arthroplasty 313 20.17 179 15.59 0.57
Total knee arthroplasty 252 16.24 243 21.17 0.96
Lumbar arthrodesis posterior - single 132 8.51 186 16.20 1.41
Removal of deep implant 132 8.51 79 6.88 0.60
Open treatment of femur fracture &
interlocking nail
65 4.19 78 6.79 1.20
Arthroscopy of the knee and partial
menisectomy
64 4.12 18 1.57 0.28
Debridement: skin, tissue, muscle,
bone
60 3.87 71 6.18 1.18
Anterior cruciate ligament repair with
arthroscopy and autograft
53 3.41 11 0.96 0.21
Open treatment femoral fracture
proximal end/neck with fixation
53 3.41 43 3.75 0.81
Neurolysis median nerve at carpal T 38 2.45 12 1.05 0.32
Application of external fixation system,
unilateral; uniplanar
31 2.00 46 4.01 1.48
Slipped capital femoral epiphysis with
femoral neck osteoplasty
31 2.00 14 1.22 0.45
Arthroscopy of shoulder, surgical; with
rotator cuff repair
32 2.06 12 1.05 0.38
Open treatment and fixation of the
clavicle
29 1.87 14 1.22 0.48
Gastronemius recession 29 1.87 26 2.26 0.90
Excisional bone biopsy - deep 25 1.61 12 1.05 0.48
Arthroscopy of the shoulder, surgical;
capsulor repair
24 1.55 6 0.52 0.25
Arthroscopy of the shoulder with
acromioplasty
22 1.42 8 0.70 0.36
Arthroscopy, debridge, drill, resect 17 1.10 7 0.61 0.41
Removal of exterior fixator system 16 1.04 12 1.05 0.75
Open toe flexor tenotomy, single 15 0.97 8 0.70 0.53
Other study procedures 130 8.38 82 0.07 0.78
Total study procedures 1552 100 1148 100 0.73
aThis table lists only those procedures that were done 15 or more times
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ratio (PR) = 1.10; 95% CI: 1.01 to 1.19). Age, sex, and
CCI score were only minimally associated with the pro-
longed pain. In contrast, these results were different for
those analyses restricted to THA and TKA procedures.
Men were 42% more likely than women to report pro-
longed pain at 42 days (PR adjusting for age, sex, and
CCI = 1.42; 95% CI: 1.09 to 1.86; and PR adjusting for
age, sex, and FCI = 1.42; 95% CI: 1.10–1.85). There was
little association between age and prolonged pain, and
the associations between the comorbidity scores and
prolonged pain were weaker than observed for other
AEs (adjusted PR for 1 point on the CCI scale = 1.02;
95% CI: 0.84 to 1.25; and adjusted PR for 1 point on the
FCI scale = 1.06; 95% CI: 1.01 to 1.13).
Using modified Poisson regression, we also examined
associations between specific AEs occurring within
42 days of surgery and the prevalence of prolonged pain
at 42 days, but the numbers were too small to adjust for
covariates. Nevertheless, we found a strong crude associ-
ation between surgical site infection and prolonged pain
(crude PR = 3.59; 95% CI: 2.22 to 5.80; p < 0.001).
Using negative binomial regression, we also estimated
the effects of specific comorbidities on the incidence rate
of all AEs (excluding prolonged pain). We found positive
associations, adjusting for age, sex and duration of
follow-up, for essential hypertension (IRR = 1.45; 95% CI:
1.16 to 1.83), asthma (IRR = 1.80; 95% CI: 1.08 to 3.02),
and chronic airway obstruction (IRR = 1.81; 95% CI: 1.18
to 2.78). Finally, we examined the relation of asthma and
essential hypertension with selected AEs, adjusting for
age and sex, using modified Poisson regression. We
found that asthma was strongly associated with the
prevalence of prolonged pain at 42 days (PR = 13.3; 95%
CI: 8.84 to 20.0), and it was inversely associated with
acute blood loss (RR = 0.52; 95% CI: 0.32 to 0.84).
Discussion
We found that in patients undergoing the 50 most
common orthopaedic procedures at the University of
Michigan in 2010, the 90-day risk of having an adverse
event after surgery was nearly 50%. These findings are
consistent with those of previous studies.
For example, Ouchterlony et al. [34] found that in a
sample of 1,361 patients undergoing general, vascular, or
orthopaedic surgery, AEs were noted in 47% of patients in
the postoperative unit. In another study of 125,000 Medi-
care beneficiaries who had undergone unilateral primary
TKA and another 11,726 for revision TKA, Mahomed
et al. [35] found that within 90 days of the procedure 5.0%
of primary and 10.2% of revision patients had an AE, as
identified through searching for ICD-9 claims codes.
These risks are appreciably lower than our estimates
(TKA 90-day risk of 21%), and this discrepancy likely de-
rives from different definitions of AEs, different methods
of identifying the AEs, and different patients populations.
In another study, Wolf et al. [36] looked at Medicare
beneficiaries who had undergone primary THA (N =
1,405,379) and revision THA (N = 337,874) between 1991
and 2008. They found a 90-day risk of AEs in the primary
THA group of 3.4 to 4.0% across the study period and for
the revision THA group 7.0 to 10.9% across the study
period. Again, these risks were much lower than what we
found in our study (THA 90-day risk of 16%), likely result-
ing from the differences in definitions of AEs, data extrac-
tion methods, and patient populations. Furthermore, we
were able to characterize the proportions of specific ad-
verse events in those undergoing THA or TKA (see
Table 3), which expands the literature in this area. These
Table 3 Adverse events for total hip or total knee arthroplasty
only
Adverse Event Total Hip
Arthroplasty,
N = 313 # (%)
Total Knee
Arthroplasty,
N = 252 # (%)
Total
Death 1 (0.6) 1 (0.4) 2
Hospital stay longer than 30 days 0 0 0
Revision within 90 days of
procedure
7 (3.9) 21 (8.6%) 28
Wrong site surgery 0 0 0
Long term bleeding 0 1 (0.4) 1
Non-healing of wound 4 (2.2) 12 (4.9) 16
Persistent swelling 2 (1.1) 31 (12.8) 33
Surgical site infection 7 (3.9) 6 (2.5) 13
Sepsis 0 0 0
Draining of wounds 13 (7.3) 4 (1.6) 17
DVT 1 (0.6) 1 (0.4) 2
Prolonged Pain 59 (33.0) 78 (32.1) 137
Nerve Pain 4 (2.2) 2 (0.8) 6
Acute Blood Loss Anemia 7 (3.9) 8 (3.3) 15
Other 75 (41.9) 77 (31.7) 152
Totals 179 243 422
Table 4 Proportion of patients with multiple adverse events
Number of
Adverse Events






0 828 53.01 1050 67.22
1 470 30.09 338 21.64
2 160 10.24 101 6.47
3 63 4.03 42 2.69
4 24 1.54 20 1.28
5 11 0.70 7 0.45
6 5 0.32 4 0.26
7 1 0.06 0 0
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latter findings may help orthopaedic surgeons monitor
and potentially prevent adverse events in those undergo-
ing total joint arthroplasty.
We found that prolonged pain was by far the most fre-
quent outcome, with a 42-day prevalence of 23% across
all procedures and 28.7% in patients undergoing THA
and 20.0% in patients undergoing TKA. Other re-
searchers have looked at pain in patients undergoing
total joint arthroplasty. For example, in one study of
THA and TKA patients, Carroll et al. [37]) found that
the median time to pain resolution was 81 days (95% CI:
49 to 146 days) in TKA patients and 81 days (95% CI:
43 to 146 days) in THA patients. While the outcome
used in their study is different than ours, their findings
indicate that more than 50% of patients in their sample
would have had prolonged pain as defined in our pro-
ject, because the median time to pain resolution was
greater than 42 days in both THA and TKA patients.
The higher proportion of patients with prolonged pain is
not surprising, given that they defined pain differently.
Table 5 Crude and adjusted associations for age/10, sex, CCI
and FCI with the number of adverse events (excluding pain)
across all procedures (Panel A) and for only THA and TKA
procedures (Panel B) using negative binomial regression
modeling
Predictors Incidence Rate Ratio 95% CI p-value
A. All Procedures (N = 1192)
Crude Associations
Age (decade) 1.00 0.95–1.06 0.87
Sex (male coded as 1) 0.99 0.81–1.21 0.91
CCI score (per 1 point) 1.20 1.11–1.31 <0.001
FCI score (per 1 point) 1.34 1.23–1.45 <0.001
Adjusted Models
Model 1
Age (decade) 1.00 0.95–1.06 0.92
Sex 0.99 0.81–1.21 0.95
CCI score (per 1 point) 1.20 1.11–1.31 <0.001
Model 2
Age (decade) 0.99 0.94–1.04 0.67
Sex 0.99 0.81–1.22 0.97
FCI score (per 1 point) 1.34 1.23–1.46 <0.001
B. THA and TKA Procedures Only (N = 413)
Crude Associations
Age (decade) 1.16 1.01–1.33 0.03
Sex 1.15 0.82–1.62 0.41
CCI score (per 1 point) 1.20 1.04–1.39 0.02
FCI score (per 1 point) 1.24 1.09–1.41 0.001
Adjusted Models
Model 1
Age (decade) 1.15 1.00–1.32 0.04
Sex 1.13 0.80–1.60 0.47
CCI score (per 1 point) 1.18 1.02–1.37 0.03
Model 2
Age (decade) 1.12 0.99–1.29 0.08
Sex 1.16 0.82–1.64 0.40
FCI score (per 1 point) 1.22 1.07–1.39 <0.001
CCI Charlson comorbidity index, FCI functional comorbidity index, THA total
hip arthroplasty, TKA total knee arthroplasty
Table 6 Crude and adjusted associations for age/10, sex, CCI
and FCI with the 90-day risk of an adverse event (excluding
pain) across all procedures (Panel A) and for only THA and TKA
procedures (Panel B) using modified Poisson regression
modeling
Predictors Risk Ratio 95% CI p-value
Panel A: All Procedures (N = 1192)
Crude Associations
Age (decade) 1.03 0.99–1.07 0.12
Sex 1.02 0.81–1.29 0.85
CCI score (per 1 point) 1.10 1.02–1.18 0.01
FCI score (per 1 point) 1.19 1.13–1.25 <0.001
Adjusted Models
Model 1
Age (decade) 1.03 0.99–1.07 0.13
Sex 1.04 0.82–1.30 0.76
CCI score (per 1 point) 1.10 1.01–1.18 0.02
Model 2
Age (decade) 1.02 0.98–1.06 0.28
Sex 1.03 0.82–1.30 0.80
FCI score (per 1 point) 1.19 1.13–1.25 <0.001
Panel B: THA and TKA Procedures Only (N = 413)
Crude Associations
Age (decade) 1.12 0.96–1.31 0.15
Sex 1.23 1.01–1.50 0.04
CCI score (per 1 point) 1.09 0.98–1.20 0.104
FCI score (per 1 point) 1.14 1.07–1.22 <0.001
Adjusted Models
Model 1
Age (decade) 1.12 0.97–1.28 0.12
Sex 1.22 0.98–1.51 0.07
CCI score (per 1 point) 1.07 0.99–1.15 0.07
Model 2
Age (decade) 1.11 0.96–1.27 0.16
Sex 1.23 1.01–1.51 0.04
FCI score (per 1 point) 1.13 1.06–1.21 <0.001
1. For the variable sex, female was coded as a 0 and male as a 1
CCI Charlson comorbidity index, FCI functional comorbidity index, THA total
hip arthroplasty, TKA total knee arthroplasty
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Carroll et al. defined pain as any type of pain included in
the Brief Pain Inventory (BPI), which includes a variety
of questions on the person’s perception of pain.
We found that the mean number adverse events was
greatest for lumbar spinal surgery and fixation of an
external fixation system. These findings are not surpris-
ing, given that these procedures are considerably
invasive, the latter of which resulting from trauma.
Other investigators have found a very similar frequency
of adverse events following spinal surgery (e.g., Hellsten
et al. [38]) and that trauma patients have higher risks of
complications [39]. For example, a recent analysis of Na-
tional Surgical Quality Improvement Program (NSQIP)
data on 146,773 orthopaedic patients (22,361 trauma
patients) found that trauma patients had a higher risk of
complications [39].
Across all of our adjusted regression models the FCI
positively predicted the incidence of all adverse events,
and the strength of that association was consistently
greater than for the CCI. Given that the FCI was devel-
oped to predict function, its predictive capability for AEs
in this population of orthopaedic patients was expected.
To our knowledge, our study is the first to show the
association between the FCI and adverse events follow-
ing orthopaedic surgery. In our models for THA and
TKA only, being older predicted an increased rate of
AEs and being male increased the risk of any AE. Other
research in patients undergoing revision THA and TKA
showed an increased risk for AEs in older patients and
in men [35, 40].
In our adjusted regression models, we found that
essential hypertension, asthma and chronic airway ob-
struction were positively associated with the rate of all
AEs within 90 days of an orthopaedic procedure. When
we examined these relations further, we found that
asthma was strongly and positively associated with the
42-day prevalence of prolonged pain and inversely asso-
ciated with the risk of acute blood loss. The relation
between individual comorbidities and AEs has been ex-
plored in other research. For example, Minhas et al.
[41], using data from the NSQIP database on 42,150 pa-
tients, explored the relation of a number of variables on
the occurrence of a cerebral vascular accident (CVA) fol-
lowing an orthopaedic procedure and reported in their
adjusted analysis that hypertension, dyspnea and chronic
obstructive pulmonary disease (COPD) were strongly as-
sociated with CVAs. But they also found that insulin
dependent diabetes mellitus and a history of a transient
ischemic attack predicted CVAs as well. While we found
that diabetes mellitus predicted individual and multiple
AEs in our crude models, when adjusted for age sex and
other comorbidities, the relation was eliminated. Of
course, in our study we looked across all AEs, not just
CVAs. Other research on the risk of AEs in TKA
patients while hospitalized, also failed to show an associ-
ation between diabetes and the risk of AEs, but did find
that COPD strongly predicted the risk of AEs [42]. To
the best of our knowledge, the relation we found be-
tween asthma and the 42-day prevalence of prolonged
pain has not been reported elsewhere. Future rigorous
research is required to confirm this finding.
Our study has several strengths. We included a sample
of all patients undergoing the top 50 orthopaedic proce-
dures at a large academic center. Therefore, we expect
our findings to be generalizable to orthopaedic patients
Table 7 Crude and adjusted associations for age/10, sex, CCI
and FCI with the adverse event of pain or not at 42 days across
all procedures (Panel A) and for only THA and TKA procedures
(Panel B) using modified Poisson regression modeling
Predictors Prevalence Ratio 95% CI p-value
Panel A: All Procedures (N = 1552)
Crude Associations
Age (decade) 1.02 0.97–1.08 0.36
Sex 0.85 0.68–1.05 0.13
CCI score (per 1 point) 1.02 0.88–1.19 0.77
FCI score (per 1 point) 1.10 1.02–1.20 0.02
Adjusted Models
Model 1
Age (decade) 1.02 0.97–1.08 0.38
Sex 0.85 0.68–1.05 0.14
CCI score (per 1 point) 1.02 0.87–1.20 0.81
Model 2
Age (decade) 1.02 0.97–1.07 0.46
Sex 0.85 0.68–1.06 0.16
FCI score (per 1 point) 1.10 1.01–1.19 0.03
Panel B THA and TKA Procedures Only (N = 550)
Crude Associations
Age (decade) 0.98 0.92–1.05 0.57
Sex 1.42 1.10–1.85 0.01
CCI score (per 1 point) 1.03 0.86–1.24 0.76
FCI score (per 1 point) 1.06 1.01–1.12 0.03
Adjusted Models
Model 1
Age (decade) 0.98 0.91–1.06 0.68
Sex 1.42 1.09–1.86 0.01
CCI score (per 1 point) 1.02 0.84–1.25 0.82
Model 2
Age (decade) 0.98 0.91–1.05 0.56
Sex 1.42 1.10–1.85 0.01
FCI score (per 1 point) 1.06 1.01–1.13 0.03
1. For the variable sex, female was coded as a 0 and male as a 1
CCI Charlson comorbidity index, FCI functional comorbidity index, THA total
hip arthroplasty, TKA total knee arthroplasty
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undergoing the same procedures at other academic cen-
ters. We extracted a large amount of data from patient
charts and considered the most practical approach for
identifying AEs in a large number of patients following
surgical procedures [43]. Furthermore, we were careful
to be certain that extractions were cross-checked. Thus,
we are confident that our data extraction was complete
and reliable. In addition, we extracted a large selection
of potential AEs, which goes beyond what has been done
in other research. Furthermore, we performed many
careful analyses, attempting to delineate associations so
as to inform further research in the area.
One potential drawback of our study is that the
generalizability does not necessarily extend beyond
academic centers or to procedures not included in our
analyses. Furthermore, it is possible that the charts in
the EMR for each patient may suffer from unclear or
underreporting of AEs (reporting bias), resulting in
biased estimates of rates and risks in this study. For ex-
ample, it is possible that certain procedures or condi-
tions may cause attending physicians to look harder for
potential adverse events or chart them more frequently
for those patients, resulting in detection bias. The role
of reporting bias and detection biases as it relates to
chart reviews of AEs should be explored further. An-
other potential drawback of our study is that almost 35%
of the included patients had less than 90 days of follow-
up and a mean follow-up of approximately 42 days. The
lack of complete follow-up in these patients could have
biased our findings; thus, caution is advised when inter-
preting our findings. Finally, because we did not com-
pare the incidence of outcome events in surgical vs.
non-surgical patients, we cannot make any inferences
about the effects of surgery or hospitalization on the
occurrence of adverse events in this study; i.e., the
adverse events were not necessarily caused by the
patients’ surgery or hospitalization that preceded them.
Conclusion
We found that patients undergoing orthopaedic proce-
dures are likely to experience a broad spectrum of adverse
events. Some of those events have serious implications to
the patient’s health, whereas many others are temporary
or can easily be treated. Indeed, the types of AEs consid-
ered in this study are broader than the types of events de-
scribed in previous studies. We also found that certain
patient characteristics, especially comorbidities, are associ-
ated with the incidence of adverse events. These findings
may aid clinicians in identifying which patients are at an
increased risk for certain AEs. We feel that these findings
support the need for large prospective (possibly random-
ized) studies, with careful patient follow-up to delineate
the risk of particular AEs and to assess which AEs are in
fact affected by orthopaedic procedures.
Appendix 1
Table 8 CPT Code Descriptions and Volume
CPT Code Procedure Description Volume
20610 ASPIRATE OR INJECT MAJOR JOINT 13 5
20610 ASPIRATE OR INJECT MAJOR JOINT 3,704
20610 ASPIRATE/INJECT MAJOR JOINT 14
20610 Total 3,723
20680 REMOVAL OF IMPLANT - DEEP 13 178
20680 REMOVAL OF IMPLANT - DEEP 342
20680 Total 520
29881 ARTHROSCOPY,KNEE & PART MENISECTOMY 270
29881 ARTHROSCOPY,KNEE & PART MENISECTOMY 83
29881 Total 353
27130 TOTAL HIP ARTHROPLASTY 341
27130 TOTAL HIP REPLACE W CALCAR 6
27130 Total 347
29826 ARTHROSCOPY SHOULDER W ACROMIOPLASTY 184
29826 ARTHROSCOPY SHOULDER W/ACROMIOPLASTY 108
29826 Total 292
27447 TOT KNEE ARTHROPLASTY-MED & LATERAL 281
27447 TOT KNEE ARTHROPLASTY-MED & LATERAL 13 5
27447 Total 286
29888 ARTHROSCOPIC ACL RECONSTRUCTION 4
29888 ARTHROSCOPIC ACL RECONSTRUCTION 32
29888 ACL REPAIR W ARTHROSCOPE AND AUTOGRAFT 13 1
29888 ACL REPAIR W ARTHROSCOPE AND AUTOGRAFT 215
29888 Total 252
29822 ARTHROSCOPY,SHOULDER,SURGICAL;LIMIT 13 223
29822 ARTHROSCOPY,SHOULDER,SURGICAL;LIMIT 7
29822 Total 230
20605 ASPIRATE OR INJECT INTERMED JOINT 13 3
20605 ASPIRATE OR INJECT INTERMED JOINT 205
20605 Total 208
22614 FUSION POSTR EA ADD SEG 193
22614 Total 193







29877 ARTHROSCOPY,DEBRIDGE,DRILL, RESECT 120
29877 ARTHROSCOPY,DEBRIDGE,DRILL,RESECT 52
29877 Total 172
29450 APPLICA CLUBFOOT CAST UNILATERAL 159
29450 APPLIC CLUBFOOT CAST UNILATERAL 2
29450 APPLICA CLUBFOOT CAST UNILATERAL 13 1
29450 Total 162
20936 AUTOGRAFT FOR SPINE SURG ONLY,LOC THRU
SAME INCIS;LIST SEP
160
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Table 8 CPT Code Descriptions and Volume (Continued)
20936 Total 160
64721 NEUROLYSIS MEDIAN NERVE AT CARPAL T 13 17
64721 NEUROLYSIS MEDIAN NERVE AT CARPAL T 139
64721 Total 156
26055 TENDON SHEATH INCISION-TRIGGER FING 100
26055 TENDON SHEATH INCISION-TRIGGER FING 13 41
26055 Total 141
20930 MORSELIZED ALLOGRAFT, FOR SPINE
SURGRY;LIST SEP IN ADDITN
109
20930 Total 109
22843 POSTR INSTRU 7 - 12 SEGMENTS; LIST SEPAR 109
22843 Total 109
11012 DEBRIDE: SKIN, TISSUE, MUSCLE, BONE 13 29
11012 DEBRIDE: SKIN, TISSUE, MUSCLE, BONE 13 75
11012 Total 104
22849 REINSERTION SPINAL FIXATION DEVICE 68
22849 REINSERTION SPINAL FIXATION DEVICE 36
22849 Total 104
25500 TX RADIUS SHAFT FRACTURE W/O MANIPU 13 1
25500 TX RADIUS SHAFT FRACTURE W/O MANIPU 102
25500 Total 103
22612 ARTHRODESIS POSTERIOR LUMBAR-SINGLE 99
22612 Total 99
29405 APPLICATION OF SHORT LEG CAST 73
29405 APPLICATION/SHORT LEG CAST 25
29405 Total 98
29875 ARTHROSCOPY & PLICA&/OR SHELF RESECT 32
29875 ARTHROSCOPY &PLICA&/OR SHELF RESECT 66
29875 Total 98
29806 ARTHROSCOPY,SHOULDER,SURG,CAPSULORRH 2
29806 ARTHROSCOPY,SHOULDER,SURG; CAPSULORRH 94
29806 Total 96
20550 INJECT SINGL TENDON SHEATH OR LIGAMENT 85
20550 INJECT SINGL TENDON SHEATH OR LIGAM 9
20550 Total 94
22842 POSTERIOR INSTRUMENTATION-SEPARATE LISTING 90
22842 Total 90
22802 ARTHRODESIS-7 OR MORE VERTEBRAE & GRAFT 86
22802 ARTHRODESIS-7 OR MORE VERTEBRAE W GRAFT 1
22802 Total 87
28232 OPEN TOE FLEXOR TENOTOMY SINGLE 6
28232 OPEN TOE FLEXOR TENOTOMY SINGLE 13 80
28232 Total 86
27179 OR SCFE W/FEMORAL NECK OSTEOPLASTY 13 49
27179 OR SCFE W/FEMORAL NECK OSTEOPLASTY 34
27179 Total 83
29075 APPLICATION SHORT ARM CAST (OSA) 41
29075 APPLICAT SHORT ARM CAST 2
Table 8 CPT Code Descriptions and Volume (Continued)
29075 APPLICATION SHORT ARM CAST (OSA) 35
29075 Total 78
29874 ARTHROSCOPY KNEE AND REMOVAL OF BODY 66
29874 ARTHROSCOPY KNEE AND REMOVAL OF BODY 10
29874 Total 76
27245 OPEN TX FEMUR FX&INTERLOCKING NAIL 13 1
27245 OPEN TX FEMUR FX&INTERLOCKING NAIL 73
27245 Total 74
23440 RESECT OR TRANSPLANT BICEPS TENDON 8
23440 RESECT OR TRANSPLANT BICEPS TENDON 13 64
23440 Total 72
29862 ARTHROSCOPY HIP W/DEBRDMT ART CART 17
29862 ARTHROSCOPY HIP W DEBRDMT ART CART 13 55
29862 Total 72
24538 TX CLOSED SUPRA/TRANSCOND FX & FIXATION 13 1
24538 TX CLOSED SUPRA/TRANSCON FX & FIXATION 69
24538 Total 70
27193 CLOSED TRTMT PELVIC RQ FX; WO MANIPULATION 69
27193 Total 69
29882 ARTHROSCOPY,KNEE,SURGICAL & MEN REPAIR 13 33
29882 ARTHROSCOPY,KNEE,SURGICAL & MEN REPAIR 36
29882 Total 69
29880 KNEE ARTHROSCOPY W MED N LAT MENSTY 58
29880 KNEE ARTHROSCOPY W MED N LAT MENSTY 13 9
29880 Total 67
29425 APPLICAT SHORT LEG WALKING CAST 5
29425 APPLICATION SHORT LEG CAST WALKING 56
29425 APPLICATION SHORT LEG CAST WALKING 3
29425 Total 64
20694 REMOVAL EXT FIXATOR SYSTEM 13 38
20694 REMOVAL OF HOFFMAN DEVICE 13 6
20694 REM EXT FIXATOR IN CLINIC 1
20694 REMOVAL EXT FIXATOR SYSTEM 14
20694 REMOVAL OF HOFFMAN DEVICE 4
20694 Total 63
20690 APPLCATN EXTERNAL FIXATN SYSTEM, UNILAT;
UNIPLANE
17
20690 APPLCATN EXTERNAL FIXATN SYSTEM
UNIPLANE;UNILAT
24
20690 APPLICATION EXT FIX SYSTEM-UNIPLANE,
UNILAT
13
20690 APPLICATION EXT FIX SYSTEM-UNILAT, UNIPLANE 8
20690 Total 62
22852 REMOVAL POSTERIOR INSTRUMENTATION 17
22852 REMOVAL POSTERIOR INSTRUMENTATION 13 43
22852 Total 60
29824 ARTHROSCPY,SHOULDER, SURGCL;W/DISTAL CLAV 3
29824 ARTHROSCPY,SHOULDER, SURGCL; W/DISTAL CLAV 56
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Appendix 2
Appendix 3Table 8 CPT Code Descriptions and Volume (Continued)
29824 Total 59
63048 LAMINECTOMY, EA ADDTL SEGMENT 13 59
63048 Total 59
20245 EXCISIONAL BONE BIOPSY - DEEP (OSA) 13 46
20245 EXCISIONAL BONE BIOPSY - DEEP (OSA) 12
20245 Total 58
27236 OPEN TX FEM FX PROX END/NECK W/FIX 54
27236 OPEN TX FEM FX PROX END/NECK W/FIX 13 3
27236 Total 57
22310 TRTMT VERT BODY FX W/O MANIP 56
22310 Total 56
23515 OPEN TX FX CLAVICLE(INCL FIXATN WHEN PERF) 54
23515 OPEN TX FX CLAVICLE INCL FIXN WHEN PERFORMD 1
23515 Total 55
27687 GASTRONEMIUS RECESSION(EG,STRAYER) 37
27687 GASTRONEMIUS RECESSION(EG,STRAYER) 17
27687 Total 54
27792 OPEN TX LATERAL MALLEOLUS FX INCLD INT
FIXN IF PERFORMED
49
27792 OPEN TX LATERAL MALLEOLUS FX INCL INTRN
FIX WHEN PERFORMD
5
Table 10 Other Adverse Events





























insufficiency of the bowel,















24 0 Seizure, severe bleeding
after tornequet removed,
































Table 9 Adverse event list and definitions/source
Adverse Event Definition
Death Reported in EHR
Hospital stay longer than 30 days Reported in EHR
Revision within 90 days of
procedure
Reported in EHR
Wrong site surgery Reported as such in EHR
Long-term bleeding Reported as such in EHR
Non-healing of wound Reported as such in EHR
Persistent swelling Reported as such in EHR
Surgical site infection Reported as such in EHR
Sepsis Reported as such in EHR
Persistent Draining of wounds Reported as such in EHR
Deep Vein Thrombosis Reported as such in EHR
Prolonged Pain Greater than 42 days on narcotics or
reported in EHR
Nerve Pain Reported as such in EHR
Additional Medication Required Reported as such in EHR
Acute Blood Loss/Anemia Reported as such in EHR
Othera Determined by review of physician of
additional EHR reported events
aMusculoskeletal, non-union, urinary retention, urinary tract infection,
gastrointestinal, foot drop, intra-operative complications, cranial/
cerebral, pulmonary, re-injury, neuronal, hematoma, cardiac, reactions
limb discrepancy, hematological, hematuria, integumentary, seromas,
renal, chest pain
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